Scarica l'app Stockscreener
1.80
3.74%
-0.07
Pre-mercato:
1.90
0.10
+5.56%
Precedente Chiudi:
$1.87
Aprire:
$1.83
Volume 24 ore:
470.40K
Relative Volume:
0.19
Capitalizzazione di mercato:
$3.76M
Reddito:
$7.06M
Utile/perdita netta:
$-21.17M
Rapporto P/E:
-0.0754
EPS:
-23.879
Flusso di cassa netto:
$-28.95M
1 W Prestazione:
-55.22%
1M Prestazione:
-61.29%
6M Prestazione:
+56.52%
1 anno Prestazione:
+7.14%
Intervallo 1D:
$1.74
$2.08
Intervallo di 1 settimana:
$1.54
$4.15
Portata 52W:
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
Nome
Curis Inc
Settore
Industria
Telefono
617-503-6500
Indirizzo
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.80 | 3.49M | 7.06M | -21.17M | -28.95M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2022-04-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2020-07-29 | Iniziato | Laidlaw | Buy |
| 2020-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-08-11 | Iniziato | FBR Capital | Outperform |
| 2015-01-22 | Reiterato | Oppenheimer | Outperform |
| 2015-01-21 | Reiterato | ROTH Capital | Buy |
| 2014-05-09 | Reiterato | Oppenheimer | Outperform |
| 2013-10-02 | Iniziato | Robert W. Baird | Outperform |
| 2013-09-30 | Iniziato | Chardan Capital Markets | Buy |
| 2012-11-14 | Iniziato | Stifel Nicolaus | Hold |
| 2012-01-31 | Reiterato | Brean Murray | Buy |
| 2012-01-31 | Reiterato | Summer Street Research | Buy |
| 2011-12-09 | Iniziato | Oppenheimer | Outperform |
| 2011-10-06 | Iniziato | Summer Street Research | Buy |
| 2011-09-22 | Iniziato | MLV Capital | Buy |
| 2011-03-21 | Reiterato | Brean Murray | Buy |
| 2010-02-26 | Reiterato | Roth Capital | Buy |
| 2010-01-07 | Iniziato | Roth Capital | Buy |
Mostra tutto
Curis Inc Borsa (CRIS) Ultime notizie
Curis announces pricing of $5.6M public offering - TipRanks
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks - TipRanks
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis: Q2 Earnings Snapshot - Caledonian Record
CURIS INC 10-Q Summary: Revenue $0 Net income ($8.58M), EPS ($4.02) — 10-Q Summary - TradingView
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors - marketscreener.com
CRIS Looks 91.8% Undervalued on GF Value™ Amid Unprofitability C - GuruFocus
Curis prices $5.6 million public offering at $1.50 per share - Investing.com
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com UK
Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PR Newswire
CURIS INC SEC Filing (Aug 13, 2026) - Stock Titan
IPO Databook: Curis (CRIS US)Aug 2026 - smartkarma.com
Curis (CRIS) seeks cash via best-efforts stock and warrant offering amid going-concern risk - Stock Titan
Curis Inc (CRIS) Stock News Today - TradingKey
Curis Inc expected to post a loss of $7.84 a shareEarnings Preview - TradingView
Curis, Inc. (CRIS) stock price, news, quote and history - au.finance.yahoo.com
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - finance.yahoo.com
Primer: Curis Inc (CRIS US)Aug 2026 - Smartkarma
Curis Inc expected to post a loss of $7.47 a shareEarnings Preview - TradingView
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring - TipRanks
Curis doses first five patients in leukemia drug study - Investing.com
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Cuts Target Price to $20 - moomoo.com
CRIS Q2'26 Earnings: EPS estimate is (6.96) USD - TradingView
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Cash Flow - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Yahoo Finance
CRIS|Curis Inc|Price:5.190|Chg%:+0.300 - TradingKey
TradingKey - TradingKey
Curis Inc (CRIS) Income Statement - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRIS Maintained by HC Wainwright & Co. -- Price Target Raised to $43.00 - GuruFocus
Curis, Inc. Revenue Breakdown – NASDAQ:CRIS - TradingView
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid Broader ConcernsRevenue Per Share - dars.gov.et
CRIS Q2'26 Earnings: revenue estimate is 1.00M USD - TradingView
Curis stock jumps 11% on positive emavusertib trial data - Investing.com
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Benzinga
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus - Yahoo Finance
Curis Q2 2026: Updated Clinical Data for Emavusertib Trials - grafa.com
Curis stock jumps 11% on positive emavusertib trial data By Investing.com - Investing.com South Africa
Curis Inc Positive Emavusertib Update Transcript - GuruFocus
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) - Yahoo Finance
Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com Nigeria
Curis reports updated trial data for emavusertib in lymphoma - Investing.com
Curis Announces Positive Emavusertib Update - PR Newswire
Why did Curis (CRIS) stock soar after hours? - MSN
Curis Inc Azioni (CRIS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):